As global markets kick off the year with strong rallies, small-cap and value shares have notably outpaced large-cap growth stocks, with indices like the Russell 2000 and S&P MidCap 400 showing impressive gains. In this dynamic environment, characterized by geopolitical tensions and fluctuating economic indicators, identifying high-growth tech stocks such as Beisen Holding requires a focus on companies that demonstrate resilience and adaptability in rapidly evolving sectors.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Beisen Holding Limited is an investment holding company that offers cloud-based human capital management solutions for enterprises in the People’s Republic of China, with a market capitalization of approximately HK$5.15 billion.
Operations: The company generates revenue primarily through its cloud-based human capital management solutions and related professional services, totaling CN¥1.02 billion.
Beisen Holding, navigating through a competitive tech landscape, has demonstrated significant strides in revenue and earnings growth. With an annualized revenue increase of 14.4%, the company is outpacing the Hong Kong market’s average growth rate of 8.4%. Notably, its earnings have surged by an impressive 112.2% annually over the past five years, signaling robust internal improvements and market acceptance. Recent financial disclosures reveal a promising reduction in losses—from CNY 99 million to CNY 18.41 million year-over-year—coupled with a substantial rise in sales to CNY 515.97 million for the half-year ended September 2025. This performance is underpinned by strategic R&D investments that not only reflect Beisen’s commitment to innovation but also enhance its offerings in a rapidly evolving sector.
SEHK:9669 Earnings and Revenue Growth as at Jan 2026
Simply Wall St Growth Rating: ★★★★★☆
Overview: Shanghai Rightongene Biotechnology Co., Ltd. is a company focused on the development and production of diagnostic kits and equipment, with a market cap of CN¥1.76 billion.
Operations: Rightongene Biotechnology generates revenue primarily from its diagnostic kits and equipment segment, amounting to CN¥191.78 million. The company’s focus on this segment underscores its specialization in the biotechnology field.
Shanghai Rightongene Biotechnology, amidst a challenging financial period marked by a net loss of CNY 5.62 million from sales of CNY 139.1 million, is poised for a turnaround with expected revenue growth at an impressive rate of 50.5% per year. This growth trajectory surpasses the broader Chinese market’s average of 14.6%. The company’s commitment to innovation is evident in its R&D strategy, crucial for staying competitive in the fast-evolving biotech industry. With earnings projected to surge by 134.71% annually, Rightongene’s strategic focus may soon yield profitable outcomes, aligning with its ambitious expansion plans and upcoming extraordinary shareholders meeting scheduled for November 2025.
SHSE:688217 Earnings and Revenue Growth as at Jan 2026
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Nayax Ltd. is a fintech company that provides comprehensive solutions for automated self-service retailers and merchants globally, with a market cap of ₪6.90 billion.
Operations: The company generates revenue primarily from its Internet Software and Services segment, totaling $369.94 million.
Nayax has recently demonstrated robust growth, with a revenue increase of 17.5% per year and an even more impressive earnings surge at 31.2% annually, outpacing the broader IL market’s growth. At NRF 2026, Nayax unveiled significant enhancements to its retail solutions platform, emphasizing its strategic focus on integrating payments and retail management systems across both physical and digital channels—a move that not only streamlines operations for retailers but also enriches customer engagement through advanced digital commerce tools. This blend of technological innovation and market expansion positions Nayax favorably in a competitive landscape, especially as it continues to pursue strategic acquisitions aimed at broadening its technological capabilities and geographic reach.
TASE:NYAX Earnings and Revenue Growth as at Jan 2026
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:9669 SHSE:688217 and TASE:NYAX.
